Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-17
2006-10-17
Jones, Dwayne (Department: 3991)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S374000
Reexamination Certificate
active
07122566
ABSTRACT:
Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.
REFERENCES:
patent: 6407128 (2002-06-01), Scaife et al.
patent: 6683102 (2004-01-01), Scaife et al.
patent: 2004/0265889 (2004-12-01), Durham, et al.
Bynum ND, et al., “Postmortem Distribution of Tramadol, Amitriptyline, and Their Metabolites in a Suicidal Overdose” Journal of Analytical Toxicology, 29(5): 401-406 (2005).
Chou R, et al., “Comparative Efficacy and Safety of Skeletal Muscle Relaxants for Spasticity and Musculoskeletal Conditions: A Systematic”, J. Pain Symptom Management 28(2):140-75 (2004).
Elenbaas JK, “Centrally Acting Oral Skeletal Muscle Relaxants,” Am J Hosp Pharm. 37(10): 1313-1323 (1980).
Gruszecki AC, et al., “Polydrug Fatality Involving Metaxalone,” J. Forensic Science 48(2): 432-4 (2003).
Kuykendall JR, and Rhodes RS, “Auditory Hallucinations Elicited by Combined Meclizine amd Metaxalone Use at Bedtime,” Ann. Pharmacother. 38(11): 1968-1969 (2004).
Moore KA, et al., “A Fatality Involving Metaxalone”, Forensic Sci Int. 149 (2-3): 249-251 (2005).
Obach, RS, “Human Liver Aldehyde Oxidase: Inhibition by 239 Drugs”, Journal of Clinical Pharmacology 44 (1):7-19 (2004).
Poklis JL, et al., “Metaxalone (Skelaxin)-Related Death”, Journal of Analytical Toxicology 28 (6): 537-540 (2004).
Schafer EW, et al., “The Acute Oral Toxicity, Repellency, and Hazard Potential of 998 Chemicals to One or More Species Wild and Domestic Birds”, Archives of Environment Contamination and Toxicology 12(3): 335-382 (1983).
Seidler, J, et al., “Identification and Prediction of Promiscuous Aggregating Inhibitors Among Known Drugs”, Journal of Medicinal Chemistry, 46 (21):, 4477-4486 (2003).
Toth, PP, and Urtis J, “Commonly Used Muscle Relaxant Therapies for Acute Low Back Pain: A Review Carisoprodol, Cyclobenzaprine Hydrochloride, and Metaxalone,” Clinical Therapeutics, 26(9): 1355-1367 (2004).
Prescribing Information for Skelaxin (metaxalone) as accessed at www.kingpharm.com on Dec. 21, 2005.
Du Jie
Roberts Richard H.
Cantor & Colburn LLP
Jones Dwayne
Mutual Pharmaceutical Company, Inc.
LandOfFree
Metaxalone products, method of manufacture, and method of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metaxalone products, method of manufacture, and method of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metaxalone products, method of manufacture, and method of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3636770